Inotuzumab Ozogamicin Post-Transplant for Acute Lymphocytic Leukemia
Phase of Trial: Phase I/II
Latest Information Update: 06 Nov 2019
Price : $35 *
At a glance
- Drugs Inotuzumab ozogamicin (Primary)
- Indications Lymphoid leukaemia
- Focus Adverse reactions
- 06 Nov 2019 Results (n=8; Data cut off- 29 July 2019) of phase 1 study has released at the 61st Annual Meeting and Exposition of the American Society of Hematology
- 25 Jun 2019 Status changed from suspended to recruiting.
- 11 Mar 2019 Planned primary completion date changed from 1 May 2019 to 1 May 2020.